First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer.

Estimation of FGF-3 oncogene amplification in DNA samples extracted from paraffin embedded sections of 136 ovarian cancer samples was carried out by a quantitative PCR method. The aim of this study was to elucidate a possible association of FGF-3 copy numbers with established prognostic factors such...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosen, A., Sevelda, P., Klein, M., Dobianer, K., Hruza, C., Czerwenka, K., Hanak, H., Vavra, N., Salzer, H., Leodolter, S.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968420/
https://www.ncbi.nlm.nih.gov/pubmed/8494710
_version_ 1782134736426106880
author Rosen, A.
Sevelda, P.
Klein, M.
Dobianer, K.
Hruza, C.
Czerwenka, K.
Hanak, H.
Vavra, N.
Salzer, H.
Leodolter, S.
author_facet Rosen, A.
Sevelda, P.
Klein, M.
Dobianer, K.
Hruza, C.
Czerwenka, K.
Hanak, H.
Vavra, N.
Salzer, H.
Leodolter, S.
author_sort Rosen, A.
collection PubMed
description Estimation of FGF-3 oncogene amplification in DNA samples extracted from paraffin embedded sections of 136 ovarian cancer samples was carried out by a quantitative PCR method. The aim of this study was to elucidate a possible association of FGF-3 copy numbers with established prognostic factors such as age, histology, FIGO stage, grading, postoperative residual tumour mass, ascites, hormone receptor content and preoperative CA 125 serum levels. In addition, correlation of FGF-3 amplification with overall survival of the patients was assessed. There was a borderline positive correlation between preoperative CA 125 serum levels and the degree of amplification of the FGF-3 gene (P = 0.06). A statistically significant association of FIGO-stage with FGF-3 copy number could be found (P = 0.008). No correlation between FGF-3 amplification and overall survival was noted. The data combine to suggest that FGF-3 is an indicator of aggressiveness of ovarian cancer. IMAGES:
format Text
id pubmed-1968420
institution National Center for Biotechnology Information
language English
publishDate 1993
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19684202009-09-10 First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer. Rosen, A. Sevelda, P. Klein, M. Dobianer, K. Hruza, C. Czerwenka, K. Hanak, H. Vavra, N. Salzer, H. Leodolter, S. Br J Cancer Research Article Estimation of FGF-3 oncogene amplification in DNA samples extracted from paraffin embedded sections of 136 ovarian cancer samples was carried out by a quantitative PCR method. The aim of this study was to elucidate a possible association of FGF-3 copy numbers with established prognostic factors such as age, histology, FIGO stage, grading, postoperative residual tumour mass, ascites, hormone receptor content and preoperative CA 125 serum levels. In addition, correlation of FGF-3 amplification with overall survival of the patients was assessed. There was a borderline positive correlation between preoperative CA 125 serum levels and the degree of amplification of the FGF-3 gene (P = 0.06). A statistically significant association of FIGO-stage with FGF-3 copy number could be found (P = 0.008). No correlation between FGF-3 amplification and overall survival was noted. The data combine to suggest that FGF-3 is an indicator of aggressiveness of ovarian cancer. IMAGES: Nature Publishing Group 1993-05 /pmc/articles/PMC1968420/ /pubmed/8494710 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Rosen, A.
Sevelda, P.
Klein, M.
Dobianer, K.
Hruza, C.
Czerwenka, K.
Hanak, H.
Vavra, N.
Salzer, H.
Leodolter, S.
First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer.
title First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer.
title_full First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer.
title_fullStr First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer.
title_full_unstemmed First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer.
title_short First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer.
title_sort first experience with fgf-3 (int-2) amplification in women with epithelial ovarian cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968420/
https://www.ncbi.nlm.nih.gov/pubmed/8494710
work_keys_str_mv AT rosena firstexperiencewithfgf3int2amplificationinwomenwithepithelialovariancancer
AT seveldap firstexperiencewithfgf3int2amplificationinwomenwithepithelialovariancancer
AT kleinm firstexperiencewithfgf3int2amplificationinwomenwithepithelialovariancancer
AT dobianerk firstexperiencewithfgf3int2amplificationinwomenwithepithelialovariancancer
AT hruzac firstexperiencewithfgf3int2amplificationinwomenwithepithelialovariancancer
AT czerwenkak firstexperiencewithfgf3int2amplificationinwomenwithepithelialovariancancer
AT hanakh firstexperiencewithfgf3int2amplificationinwomenwithepithelialovariancancer
AT vavran firstexperiencewithfgf3int2amplificationinwomenwithepithelialovariancancer
AT salzerh firstexperiencewithfgf3int2amplificationinwomenwithepithelialovariancancer
AT leodolters firstexperiencewithfgf3int2amplificationinwomenwithepithelialovariancancer

Ejemplares similares